Charles Schwab
FLGT icon

Charles Schwab’s Fulgent Genetics FLGT Stock Holding History

Charles Schwab’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.2M Sell
350,987
-3,197
-0.9% -$54.2K ﹤0.01% 2310
2026
Q1 		$5.63M Sell
354,184
-48,618
-12% -$1.06M ﹤0.01% 2355
2025
Q4 		$10.6M Buy
402,802
+43,521
+12% +$1.13M ﹤0.01% 2109
2025
Q3 		$8.12M Buy
359,281
+59,877
+20% +$1.23M ﹤0.01% 2203
2025
Q2 		$5.95M Buy
299,404
+55,425
+23% +$1.08M ﹤0.01% 2258
2025
Q1 		$4.12M Buy
243,979
+33,768
+16% +$575K ﹤0.01% 2349
2024
Q4 		$3.88M Sell
210,211
-34,977
-14% -$683K ﹤0.01% 2455
2024
Q3 		$5.33M Sell
245,188
-24,068
-9% -$538K ﹤0.01% 2346
2024
Q2 		$5.28M Sell
269,256
-25,684
-9% -$536K ﹤0.01% 2340
2024
Q1 		$6.4M Buy
294,940
+27,627
+10% +$686K ﹤0.01% 2197
2023
Q4 		$7.73M Buy
267,313
+33,141
+14% +$887K ﹤0.01% 2124
2023
Q3 		$6.26M Buy
234,172
+32,875
+16% +$1.12M ﹤0.01% 2149
2023
Q2 		$7.45M Buy
201,297
+21,691
+12% +$756K ﹤0.01% 2051
2023
Q1 		$5.61M Buy
179,606
+30,830
+21% +$992K ﹤0.01% 2151
2022
Q4 		$4.43M Sell
148,776
-1,443
-1% -$51.6K ﹤0.01% 2279
2022
Q3 		$5.73M Buy
150,219
+6,066
+4% +$304K ﹤0.01% 2143
2022
Q2 		$7.86M Buy
144,153
+129
+0.1% +$7.09K ﹤0.01% 1963
2022
Q1 		$8.99M Buy
144,024
+3,771
+3% +$248K ﹤0.01% 2013
2021
Q4 		$14.1M Sell
140,253
-6,969
-5% -$613K ﹤0.01% 1810
2021
Q3 		$13.2M Buy
147,222
+19,795
+16% +$1.8M ﹤0.01% 1847
2021
Q2 		$11.8M Buy
127,427
+16,044
+14% +$1.28M ﹤0.01% 1914
2021
Q1 		$10.8M Buy
111,383
+24,441
+28% +$2.52M ﹤0.01% 1919
2020
Q4 		$4.53M Buy
86,942
+14,214
+20% +$594K ﹤0.01% 2268
2020
Q3 		$2.91M Buy
72,728
+46,385
+176% +$1.45M ﹤0.01% 2348
2020
Q2 		$422K Buy
+26,343
New +$403K ﹤0.01% 2900

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's FLGT Position: Q2 2026 in Review

Charles Schwab reduced its Fulgent Genetics (FLGT) stake by 0.9% in Q2 2026, selling an estimated $54.2K and leaving 350,987 shares worth $7.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Charles Schwab first reported a position in FLGT in Q2 2020 and has held it in 25 quarters since. The position peaked at $14.1M in Q4 2021. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Charles Schwab held 350,987 shares of Fulgent Genetics worth $7.2M as of Q2 2026.
  • Charles Schwab sold 3,197 Fulgent Genetics shares in Q2 2026, an estimated $54.2K.
  • Fulgent Genetics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2310 holding.
  • Charles Schwab first reported a position in Fulgent Genetics in Q2 2020 and has held it in 25 quarters since.
  • Charles Schwab's Fulgent Genetics position peaked at $14.1M in Q4 2021.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.